

Special Issue

Web-Based and/or Family-Focused Interventions Facilitating Cancer Predisposition Cascade Genetic Screening

Message from the Guest Editor

In many countries around the world, privacy laws for the protection of information regarding genetic testing dictate that communication of test results and predisposition to hereditary cancer syndromes (i.e., HBOC and Lynch syndrome) is initiated solely by the person identified with the pathogenic variant and never from the medical clinic. An essentially medical task, i.e., communication of cancer risk and possible testing, relies on mutation carriers as primary communicators with their at-risk relatives. This strategy has significant limitations in both ensuring contact with the appropriate people and the transmission of accurate information and hinders the potential for cancer predisposition cascade genetic testing. Technology could play a significant role in facilitating communication and access to genetic information and services for families with hereditary predisposition to cancer. This Special Issue of *Cancers* gives an opportunity to describe recent and original research and/or reviews regarding cancer predisposition cascade genetic screening.

Guest Editor

Prof. Dr. Maria C. Katapodi

1. Department of Clinical Research, Faculty of Medicine, University of Basel, 4055 Basel, Switzerland
2. Robert Wood Johnson Foundation Fellow, Princeton, NJ, USA

Deadline for manuscript submissions

closed (31 December 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/36408

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)